The Lancet. Microbe

JOURNAL ARTICLE

Advances in tuberculosis diagnostics and biomarkers, 2020-26: scientific evidence, recommendations, gaps, and developmental priorities.

The Lancet. Microbe

This is a WHO policy synthesis and scientific evidence review consolidating diagnostic and biomarker advances from 2020–25, informing updated recommendations for TB detection and drug resistance across populations and specimen types.

JOURNAL ARTICLE

Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines.

The Lancet. Microbe

A comprehensive narrative review synthesizing pivotal trial evidence and WHO guideline updates on tuberculosis treatment innovation since 2020, without reporting new primary efficacy data.

JOURNAL ARTICLE

Minimal supply chain and forecasting testing volumes for clinical bacteriology laboratories in resource-limited settings for individual patient care: a costing study.

The Lancet. Microbe

A costing model informed by expert consensus and real-world data from two African laboratories, providing evidence-based cost estimates and procurement guidance for implementing clinical bacteriology in resource-limited settings, without comparative effectiveness or outcome data.

JOURNAL ARTICLE

Advances in development of tuberculosis vaccines and preventive drug therapies: current pipeline, evidence, and access.

The Lancet. Microbe

A narrative review synthesizing current evidence on TB vaccine pipelines and preventive therapies, providing clinical and policy guidance rather than reporting primary efficacy data.